- Subject Team
Wan Liping
M.D., Ph.D., Vice executive director of the department south branch, Chief Physician, Associated Professor of Medicine, Master's Supervisor
Diagnosis and treatment of anemia, thrombocytopenia, hemorrhagic disorders, acute and chronic leukemia, lymphoma and multiple myeloma, especially autologous and allogeneic hematopoietic stem cell transplantation.
Department of Hematology
Profile
Education & Training
04/2013-09/2014 Postdoctoral fellow
Department of Stem Cell Transplantation and Cellular Therapy, Division of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
The United States
09/2003-06/2006 Ph.D., Hematology
Shanghai Medical College, Fudan University, Shanghai, China
06/2006-08/2006 Visiting Scholar
Bone Marrow Transplantation Center, Division of Hematology, Hamburg University Hospital, Hamburg, Germany
09/1992-06/1999 Bachelor degree and Master degree, M.D.
Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
04/2013-09/2014 Postdoctoral fellow
Department of Stem Cell Transplantation and Cellular Therapy, Division of Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX
The United States
09/2003-06/2006 Ph.D., Hematology
Shanghai Medical College, Fudan University, Shanghai, China
06/2006-08/2006 Visiting Scholar
Bone Marrow Transplantation Center, Division of Hematology, Hamburg University Hospital, Hamburg, Germany
09/1992-06/1999 Bachelor degree and Master degree, M.D.
Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Work Experiences:
07/2006--present Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
07/1999-08/2003 Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
07/2006--present Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
07/1999-08/2003 Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
Professional Memberships
Youth Member, Shanghai Medical Association Hematology Branch Committee, 2016-present
Youth Member, Chinese Society of Clinical Oncology Hematology Branch Committee, 2016-present
Member, Shanghai Immune Association Hematological Immunology Professional Committee, 2015-present
Youth Member, Shanghai Medical Association Infection and Antibiotics Branch Committee, 2016-present
Youth Member, Shanghai Medical Association Hematology Branch Committee, 2016-present
Youth Member, Chinese Society of Clinical Oncology Hematology Branch Committee, 2016-present
Member, Shanghai Immune Association Hematological Immunology Professional Committee, 2015-present
Youth Member, Shanghai Medical Association Infection and Antibiotics Branch Committee, 2016-present
Honors and Awards
2016 Scientific and Technological Advancement Award of Ministry of Education, The second principal person.
2015 President Award for Excellence in Research, Shanghai General Hospital
2015 Outstanding Staff, Shanghai General Hospital
2012 President Award for Excellence in Clinical work, Shanghai General Hospital
2012 Outstanding Staff, Shanghai General Hospital
2008 Shanghai Medical Science and Technology Award, The second principal person
2006 Outstanding graduate, Fudan University
2016 Scientific and Technological Advancement Award of Ministry of Education, The second principal person.
2015 President Award for Excellence in Research, Shanghai General Hospital
2015 Outstanding Staff, Shanghai General Hospital
2012 President Award for Excellence in Clinical work, Shanghai General Hospital
2012 Outstanding Staff, Shanghai General Hospital
2008 Shanghai Medical Science and Technology Award, The second principal person
2006 Outstanding graduate, Fudan University
Selected Publications
1.St John LS*, Wan L*, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ1, Bollard CM, Ma Q, Molldrem JJ PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy. 2016;18(8):995-1001. (* Co-first author)
2.Wan L, Zhang Y, Lai Y, Jiang M, Song Y, Zhou J, Zhang Z, Duan X, Fu Y, Liao L, Wang C，Effect of granulocyte-macrophage stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem cell transplantation: a prospective multicenter randomized phase 4 trial. Journal of clinical oncology. 2015;33(34):3999-4006.
3.Wan L, Wang C, Liu L, et al. Efficacy and safety of micafungin as prophylaxis for invasive fungal disease in neutropenic patients with hematologic malignancies. International Journal of Pharmacology. 2014; 10 (4): 231-236.
2. Jiang Y*, Wan LP*, Qin YW, et al. Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation. International Journal of Hematology. 2014; 99(3):323-328. (* Co-first author)
4.Wan L, Yan S, Wang C, et al. Allogeneic Peripheral Blood Stem Cell Transplantation in the Treatment of Severe Aplastic Anemia and Severe Infection. Chinese Medical Journal. 2003,116(5)：676-678.
1.St John LS*, Wan L*, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ1, Bollard CM, Ma Q, Molldrem JJ PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy. 2016;18(8):995-1001. (* Co-first author)
2.Wan L, Zhang Y, Lai Y, Jiang M, Song Y, Zhou J, Zhang Z, Duan X, Fu Y, Liao L, Wang C，Effect of granulocyte-macrophage stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem cell transplantation: a prospective multicenter randomized phase 4 trial. Journal of clinical oncology. 2015;33(34):3999-4006.
3.Wan L, Wang C, Liu L, et al. Efficacy and safety of micafungin as prophylaxis for invasive fungal disease in neutropenic patients with hematologic malignancies. International Journal of Pharmacology. 2014; 10 (4): 231-236.
2. Jiang Y*, Wan LP*, Qin YW, et al. Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation. International Journal of Hematology. 2014; 99(3):323-328. (* Co-first author)
4.Wan L, Yan S, Wang C, et al. Allogeneic Peripheral Blood Stem Cell Transplantation in the Treatment of Severe Aplastic Anemia and Severe Infection. Chinese Medical Journal. 2003,116(5)：676-678.